© the authors 2012. Background: Increasing numbers of studies identify new prognostic factors for categorising chemotherapy-induced febrile neutropenia adult cancer patients into high- or low-risk groups for adverse outcomes. These groupings are used to tailor therapy according to level of risk. However many emerging factors with prognostic significance remain controversial, being based on single studies only. Objectives: A systematic review was conducted to determine the strength of association of all identified factors associated with the outcomes of chemotherapy-induced febrile neutropenia patients.Yee Mei Lee, Dora Lang, Craig Lockwoo
BACKGROUND : Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony...
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that o...
Background Febrile neutropenia is the most common side effect of myelosuppressive chemotherapy. It i...
This systematic review has been submitted to the Joanna Briggs Institute Systematic Review Library.C...
Aims: This thesis explored and examined the clinical factors associated with the outcomes of chemoth...
Background: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-...
Abstract Background Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte...
BACKGROUND: Among patients who develop fever and neutropenia after having received cancer chemothera...
International audienceCytotoxic chemotherapy suppresses the haematopoietic system, impairing host pr...
analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
Source of support: Departmental sources Background: Febrile neutropenia (FN) is a life-threatening c...
Background: Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012....
Background: Febrile neutropenia (FN) is the commonest fatal acute complication of cancer treatment i...
SUMMARY Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complication...
BACKGROUND : Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony...
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that o...
Background Febrile neutropenia is the most common side effect of myelosuppressive chemotherapy. It i...
This systematic review has been submitted to the Joanna Briggs Institute Systematic Review Library.C...
Aims: This thesis explored and examined the clinical factors associated with the outcomes of chemoth...
Background: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-...
Abstract Background Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte...
BACKGROUND: Among patients who develop fever and neutropenia after having received cancer chemothera...
International audienceCytotoxic chemotherapy suppresses the haematopoietic system, impairing host pr...
analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
Source of support: Departmental sources Background: Febrile neutropenia (FN) is a life-threatening c...
Background: Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012....
Background: Febrile neutropenia (FN) is the commonest fatal acute complication of cancer treatment i...
SUMMARY Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complication...
BACKGROUND : Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony...
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that o...
Background Febrile neutropenia is the most common side effect of myelosuppressive chemotherapy. It i...